Travere Therapeutics, Inc. · NASDAQ:TVTX
Travere Therapeutics — Technical Presentation (November 2023)
12 slides from Travere Therapeutics's technical presentation, Nov 1, 2023
Slide 1: Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients
SA-OR84 Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases To obtain a PDF of this Howard Trachtman1, Rosanna Coppo2, Ping He3,*, Kenneth V. presentation: Lieberman4, Alex Mercer5, Michelle Rheault6, Moin A. Saleem7, Sc
Slide 2: Disclosures
DISCLOSURES • HT has received consulting fees from Aclipse, Boehringer Ingelheim, Maze Therapeutics, Natera, Otsuka, PhaseV, Travere Therapeutics, Inc., and Walden; received speaking honoraria from the National Kidney Foundation; and participated on data safety monitoring or advisory boards for Chem
Slide 3: Introduction
INTRODUCTION • Sparsentan is a novel dual endothelin angiotensin receptor antagonist (DEARA) approved to treat adults with immunoglobulin A (IgA) nephropathy in the US1,2 and in development for focal segmental glomerulosclerosis (FSGS).3,4 Phase 3 trials are PROTECT and DUPLEX • Dual ETA and AT1 rec
Slide 4: Methods
METHODS • Open-label, single-arm, descriptive, multicenter trial enrolling ≈57 pediatric patients Week 112 End of study Treatment period (108 weeks) Safety follow- 2-week Sparsentan (oral suspension once daily*) up washout (4 weeks) Screening period of FSGS or MCD (population 1), n≈30 No study drug
Slide 5: Baseline characteristics of patients
RESULTS • Baseline characteristics of the 23 patients who had received ≥1 dose of sparsentan at data cutoff (April 5, 2023) Characteristic Population 1: Population 2: Total (N=23) MCD or FSGS (n=13) IgAN or AS (n=10) Diagnosis n (%) MCD 8 (61.5) 0 8 (34.8) FSGS 5 (38.5) 0 5 (21.7) IgAN 0 3 (30.0) 3
Slide 6: Proteinuria decreased from baseline over weeks of sparsentan treatment
RESULTS • Proteinuria decreased from baseline over 12 weeks of sparsentan treatment FSGS or MCD IgAN or AS (population 1) (population 2) Total Week 8 Week 12 Week 8 Week 12 Week 8 Week 12 0.0 n=11 n=12 n=10 n=7 n=21 n=19 –10.0 Geometric mean (SE) UPCR change from baseline, % –32.0% –31.5% –20.0 –37.
Slide 7: eGFR was broadly stable during the first weeks of treatment
RESULTS • eGFR was broadly stable during the first 12 weeks of treatment 160 Mean eGFR Mean eGFR (SD), mL/min/1.73 m2 140 120 100 80 60 40 FSGS or MCD (population 1) n=12 20 IgAN or AS (population 2) Total 0 Baseline Week 2 Week 4 Week 8 Week 12 n=21 FSGS or MCD n=13 n=12 n=13 n=13 n=12 IgAN or AS n
Slide 8: Effect of sparsentan on blood pressure during the first weeks of treatment
RESULTS • Effect of sparsentan on blood pressure during the first 12 weeks of treatment Systolic FSGS or MCD (population 1) 135 IgAN or AS (population 2) 115 Total 125 116 116 115 108 108 pressure, mm Hg Mean (SD) blood 108 105 95 v Diastolic 85 69 75 69 69 63 63 65 63 55 n=13 45 Baseline Week 2 Wee
Slide 9: Sparsentan was generally well tolerated over the 12-week treatment period
RESULTS • Sparsentan was generally well tolerated over the 12-week treatment period • 1 patient discontinued study treatment due to worsening of nephrotic syndrome FSGS or MCD IgAN or AS: Total Patients, n (%) population 1 (n=13) population 2 (n=10) (N=23) Any treatment-emergent 11 (85) 7 (70) 18 (7
Slide 10: Conclusions
CONCLUSIONS In pediatric patients with a range of proteinuric glomerular diseases, sparsentan treatment resulted in proteinuria reductions over the initial 12 weeks Sparsentan had a safety profile consistent with that observed in studies of adults with IgAN or FSGS,1-4 and the oral suspension formul
Slide 11: Acknowledgments
ACKNOWLEDGMENTS • This study is funded by Travere Therapeutics, Inc. We thank the patients, their families and caregivers, the investigators, and study site staff who are participating in this study. We also thank Nuhira Masthan of Travere Therapeutics for biostatistical support. Medical writing sup
Slide 12: Questions?
Questions? 2 TRAVERE
Travere Therapeutics — Technical Presentation (November 2023) on 6ix